Compare · AKAN vs DFTX
AKAN vs DFTX
Side-by-side comparison of Akanda Corp. (AKAN) and Definium Therapeutics Inc. (DFTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AKAN and DFTX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $4.71B, about 1126.2x AKAN ($4.2M).
- Over the past year, AKAN is down 91.6% and DFTX is up 345.2% - DFTX leads by 436.8 points.
- DFTX has been more active in the news (6 items in the past 4 weeks vs 1 for AKAN).
- DFTX has more recent analyst coverage (5 ratings vs 0 for AKAN).
PerformanceAKAN-91.62%DFTX+345.20%
2025-07-28+0.00%2026-07-24
- Company
- Akanda Corp.
- Definium Therapeutics Inc.
- Price
- $7.66-4.13%
- $43.14+0.54%
- Market cap
- $4.2M
- $4.71B
- 1M return
- -50.07%
- +2.42%
- 1Y return
- -91.62%
- +345.20%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- News (4w)
- 1
- 6
- Recent ratings
- 0
- 5
AKAN
Akanda Corp.
Akanda Corp., through its subsidiaries, engages in the cultivation, manufacture, and distribution of cannabis products in the United Kingdom, Lesotho, and internationally. It intends to supply cannabis based medical and wellness products. The company was incorporated in 2021 and is headquartered in New Romney, the United Kingdom.
Latest AKAN
- Coloured Ties Capital Announces Proposed Share Consolidation
- SEC Form 6-K filed by Akanda Corp.
- From Nokia to NeOnc: The Stocks Dominating Screens as Volume Spikes
- SEC Form 6-K filed by Akanda Corp.
- SEC Form 20-F filed by Akanda Corp.
- SEC Form 6-K filed by Akanda Corp.
- SEC Form 6-K filed by Akanda Corp.
- SEC Form NT 20-F filed by Akanda Corp.
- SEC Form 6-K filed by Akanda Corp.
- SEC Form 6-K filed by Akanda Corp.
Latest DFTX
- A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening
- Definium Therapeutics Announces New Employee Inducement Grants
- Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
- Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology
- New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)
- Definium Therapeutics Announces New Employee Inducement Grants
- Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
- Chief Legal Officer Sullivan Mark sold $585,750 worth of shares (13,008 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 320,571 units (SEC Form 4) (withholding tax)
- Chief Medical Officer Karlin Daniel sold $451,876 worth of shares (10,035 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 503,282 units (SEC Form 4) (withholding obligation)
- Chief Financial Officer Roberts Brandi sold $135,675 worth of shares (3,013 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 209,487 units (SEC Form 4) (withholding obligation)